Who sold GW Pharmaceuticals Company stock in the last year?
Company insiders that have sold GW Pharmaceuticals company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, and Volker Knappertz. View insider buying and selling activity for GW Pharmaceuticals or view top insider-selling stocks.
Is GW Pharmaceuticals'revenue Trending up or down?
Over the last half decade GW Pharmaceuticals's revenue has actually been trending down at about 20% per year. On the other hand, the share price done the opposite, gaining 22%, compound, each year. It just goes to show tht the market is forward looking, and it's not always easy to predict the future based on past trends.
How did GW Pharmaceuticals'Epidiolex make money last year?
It was approved by the Food and Drug Administration in 2018 to treat seizures resulting from early-onset epilepsy. Last year, Epidiolex brought in $510.5 million in sales, up 70% over 2019, making up nearly all of GW's $527.2 million in revenue for the year.
How many times has the Fool written about GW Pharmaceuticals?
The Fool has written over 500 articles on GW Pharmaceuticals. All Market Moves Podcasts Earnings GW Pharmaceuticals Stockholders Approve Acquisition by Jazz Pharmaceuticals
Who bought out GW Pharmaceuticals?
Jazz PharmaceuticalsA big merger at the intersection of the marijuana and pharmaceutical industries is one step closer to completion. On Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ -1.92%), both companies announced in a joint press release.
Did GW Pharmaceuticals get bought out?
DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Did GW Pharmaceuticals stock split?
GWPH Stock Flies On Takeover Deal Under the terms of the deal, Jazz will pay $220 per American depositary share. That's split in $200 per ADS in cash and $20 in Jazz ordinary shares. The entire deal values GWPH stock at $7.2 billion, or $6.7 billion net of GW Pharma's cash.
How much did Jazz Pharmaceuticals pay for GW Pharmaceuticals?
$7.6 billionThe two companies announced Wednesday that Jazz's acquisition of GW has been completed. This brings the $7.6 billion cash-and-stock deal, first announced in early February, to a close.
How much did GW Pharma sell for?
$7.2bnBritish pharmaceutical firm GW has been sold to US rival Jazz Pharmaceuticals for $7.2bn (£5.3bn), sending shares in the Cambridge-based company soaring. Jazz will acquire GW for $220 per American depository share, with $200 paid in cash and the remaining $20 in Jazz shares.
Is GWPH a buy or sell?
The VGM score is based on the trading styles of Growth, VAlue, and Momentum....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is GW Pharmaceuticals public?
In 2001, GW Pharmaceuticals listed on the Alternative Investment Market, the junior market of the London Stock Exchange. In May 2013, the company became dual-listed on the NASDAQ and AIM.
How do I buy GW Pharmaceutical stock?
How to buy shares in GW PharmaceuticalsCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Is Jazz Pharmaceuticals an acquisition target?
Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. That is the British company that has the only FDA-approved CBD derived drug, Epidiolex. Jazz may be a new name for pot investors.
Is Jazz Pharmaceuticals stock a buy?
Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Who owns Jazz Pharmaceuticals?
Bruce C. CozaddJazz PharmaceuticalsTypePublic companyKey peopleBruce C. Cozadd (Chairman & CEO)ProductsPharmaceutical drugsBrandsXyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt VyxeosRevenueUS$1.618 billion (2017)13 more rows
What company owns Epidiolex?
GW Pharmaceuticals' (GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients.
How were GW Pharmaceuticals' earnings last quarter?
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0....
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the following people: Mr. Justin D. Gover , CEO & Exec. Director (Age 50, Pay $1.19M) ( LinkedIn Pr...
What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com . Justin Gover has an approval rating of 80% among GW Pharmaceuticals...
Who are some of GW Pharmaceuticals' key competitors?
Some companies that are related to GW Pharmaceuticals include Royalty Pharma (RPRX) , MERCK Kommanditgesellschaft auf Aktien (MKGAF) , Takeda Ph...
What other stocks do shareholders of GW Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC) , NVIDIA...
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."
What is GW Pharmaceuticals' stock price today?
One share of GWPH stock can currently be purchased for approximately $218.96.
How much money does GW Pharmaceuticals make?
GW Pharmaceuticals (NASDAQ:GWPH) has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceut...
How many employees does GW Pharmaceuticals have?
GW Pharmaceuticals employs 1,161 workers across the globe.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas.
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.27.
What happened
Shares of GW Pharmaceuticals (NASDAQ: GWPH) were skyrocketing 46.3% as of 10:45 a.m. EST on Wednesday. The huge gain came after Jazz Pharmaceuticals (NASDAQ: JAZZ) announced plans to acquire GW for $7.2 billion.
So what
It's certainly not surprising in the least that GW Pharmaceuticals' shares took off today. Jazz's offer of $220 per share for GW represents a 50% premium to the closing price of the cannabinoid-focused biotech stock on Tuesday.
Now what
It's not a done deal just yet. Both companies' boards of directors have unanimously approved the acquisition. However, GW' shareholders must also vote in favor of the buyout. In addition, Jazz and GW will have to obtain regulatory approvals. However, the companies expect the transaction will close in the second quarter of 2021.
How much does GW Pharm trade?
GW Pharm now trades around $214 per share, very close to the acquisition price. Therefore, unless you are a professional merger arbitrageur -- one who bets on announced mergers being consummated -- the ship has likely sailed on GW.
How much did Jazz Pharmaceuticals buy GW?
The bulk of the move came on Feb. 3 when Jazz Pharmaceuticals ( NASDAQ:JAZZ) announced it would be purchasing GW for $7.2 billion, or the equivalent of $220 per share, made up of $200 per share in cash and $20 in Jazz stock.
When will Jazz generics be available?
It made up 74% of sales last year, but generics will be coming in 2023. That will likely stifle Jazz's growth, unless some of its other drugs in oncology, specifically lung cancer, catch on. But those bring in relatively small dollar amounts today.